The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Open accessAbstract
Anthracyclines are used in over 50% of childhood cancer treatment protocols, but their clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as asymptomatic cardiac dysfunction and congestive heart failure in up to 57% and 16% of patients, respectively. Candidate gene studies have reported genetic associations with ACT, but these studies have in general lacked robust patient numbers, independent replication or functional validation. Thus, the individual variability in ACT susceptibility remains largely unexplained. We performed a genome-wide association study in 280 patients of European ancestry treated for childhood cancer, with independent replication in similarly treated cohorts of 96 European and 80 non-European patients. We identified a nonsynonymous variant (rs2229774, p.Ser427Leu) in RARG highly associated with ACT (P = 5.9 × 10−8, odds ratio (95% confidence interval) = 4.7 (2.7–8.3)). This variant alters RARG function, leading to derepression of the key ACT genetic determinant Top2b, and provides new insight into the pathophysiology of this severe adverse drug reaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Browning, S. R., & Browning, B. L. (2007) · The American Journal of Human Genetics · doi:10.1086/521987 · Cited by 3,210
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889 · cited 10×
“In HEK293T cells expressing RARG S427L , the ATRA-inducible transcriptional activation of a RARE-coupled luciferase reporter was significantly reduced compared to wild type RARG -expressing cells (Fig.”
InfluentialLocusZoom: regional visualization of genome-wide association scan results
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., Boehnke, M., Abecasis, G. R., & Willer, C. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq419 · Cited by 2,707
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Visscher, H., Ross, C. J. D., Rassekh, S. R., Barhdadi, A., Dubé, M.-P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3467 · Cited by 401
Self-citationAnthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
Kremer, L. C. M., van Dalen, E. C., Offringa, M., Ottenkamp, J., & Voûte, P. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.191 · Cited by 399
Self-citationAnthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Blanco, J. G., Sun, C.-L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8987 · Cited by 372
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
van der Pal, H. J., van Dalen, E. C., van Delden, E., van Dijk, I. W., Kok, W. E., Geskus, R. B., Sieswerda, E., Oldenburger, F., Koning, C. C., van Leeuwen, F. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4730 · Cited by 320
Self-citationRacial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.633 · Cited by 308
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Cancer pharmacogenomics: strategies and challenges
Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3352 · Cited by 215
Doxorubicin clearance in the obese.
Rodvold, K. A., Rushing, D. A., & Tewksbury, D. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1321 · Cited by 213
Visscher, H., Ross, C. J. D., Rassekh, S. R., Sandor, G. S. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Rogers, P. C., Rieder, M. J., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24505 · Cited by 204
Self-citationCardiac Function in 5-Year Survivors of Childhood Cancer: A Long-term Follow-up Study
van der Pal, H. J., van Dalen, E. C., Hauptmann, M., Kok, W. E., Caron, H. N., van den Bos, C., Oldenburger, F., Koning, C. C., van Leeuwen, F. E., & Kremer, L. C. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.233 · Cited by 191
Self-citationWang, X., Liu, W., Sun, C.-L., Armenian, S. H., Hakonarson, H., Hageman, L., Ding, Y., Landier, W., Blanco, J. G., Chen, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3557 · Cited by 161
Self-citationDelacroix, L., Moutier, E., Altobelli, G., Legras, S., Poch, O., Choukrallah, M.-A., Bertin, I., Jost, B., & Davidson, I. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00756-09 · Cited by 159
Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., et al. (2013) · Cancer · doi:10.1002/cncr.28256 · Cited by 158
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
McLeod, H. L. (2013) · Science · doi:10.1126/science.1234139 · Cited by 156
Windsor, R. E., Strauss, S. J., Kallis, C., Wood, N. E., & Whelan, J. S. (2011) · Cancer · doi:10.1002/cncr.26472 · Cited by 145
A Comprehensive View of Nuclear Receptor Cancer Cistromes
Tang, Q., Chen, Y., Meyer, C. A., Geistlinger, T., Lupien, M., Wang, Q., Liu, T., Zhang, Y., Brown, M. A., & Liu, X. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2091 · Cited by 141
Armenian, S. H., Ding, Y. P., Mills, G., Sun, C., Venkataraman, K., Wong, F. L., Neuhausen, S. L., Senitzer, D., Wang, S., Forman, S. J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12516 · Cited by 130
Visscher, H., Rassekh, S. R., Sandor, G. G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C. M., van der Pal, H. J. H., Rogers, P. C., Rieder, M. J., Carleton, B., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.61 · Cited by 125
Self-citationSemsei, Á. F., Erdelyi, D. J., Ungvári, I., Cságoly, E., Hegyi, M., Kiszel, P., Lautner‐Csorba, O., Szabolcs, J., Masát, P., Fekete, G., et al. (2011) · Cell Biology International · doi:10.1042/cbi20110264 · Cited by 120
Rossi, D., Rasi, S., Franceschetti, S., Capello, D., Castelli, A., Paoli, L. D., Ramponi, A., Chiappella, A., Pogliani, E. M., Vitolo, U., et al. (2009) · Leukemia · doi:10.1038/leu.2008.398 · Cited by 116
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions
Nelson, M. R., Bacanu, S., Mosteller, M., Li, L.-L., Bowman, C. E., Roses, A. D., Lai, E., & Ehm, M. G. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.4 · Cited by 110
Rajić, V., Aplenc, R., Debeljak, M., Prestor, V. V., Kuželički, N. K., Mlinarič‐Raščan, I., & Jazbec, J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903177212 · Cited by 97
Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity
Duan, S., Bleibel, W. K., Huang, R. S., Shukla, S. J., Wu, X., Badner, J. A., & Dolan, M. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4431 · Cited by 88
Palm‐Leis, A., Singh, U. S., Herbelin, B. S., Olsovsky, G., Baker, K. M., & Pan, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407383200 · Cited by 72
Cascales, A., Pastor-Quirante, F. A., Sánchez-Vega, B., Luengo‐Gil, G., Corral, J., Ortuño-Pacheco, G., Vicente, V., & de la Peña, F. A. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0239 · Cited by 70
Lubieniecka, J. M., Graham, J., Heffner, D. J., Mottus, R., Reid, R. E., Hogge, D. E., Grigliatti, T. A., & Riggs, W. K. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00231 · Cited by 70
Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation
Cascales, A., Sánchez-Vega, B., Navarro, N., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.09.046 · Cited by 59
Global analysis of RAR‐responsive genes in the Xenopus neurula using cDNA microarrays
Arima, K., Shiotsugu, J., Niu, R., Khandpur, R., Martinez, M., Shin, Y., Koide, T., Cho, K. W. Y., Kitayama, A., Ueno, N., et al. (2004) · Developmental Dynamics · doi:10.1002/dvdy.20231 · Cited by 57
Retinoic Acid Signalling Is Activated in the Postischemic Heart and May Influence Remodelling
Bilbija, D., Haugen, F., Sagave, J., Baysa, A., Bastani, N. E., Levy, F. O., Sirsjö, A., Blomhoff, R., & Valen, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044740 · Cited by 56
Pharmacogenomic Characterization of US FDA-approved Cytotoxic Drugs
Peters, E. J., Motsinger‐Reif, A. A., Havener, T. M., Everitt, L., Hardison, N. E., Watson, V. G., Wagner, M. J., Richards, K. L., Province, M. A., & McLeod, H. L. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.92 · Cited by 46
Pellicori, P., Calicchia, A., Lo‐Coco, F., Cimino, G. G., & Torromeo, C. (2012) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00278.x · Cited by 38
Simándi, Z., Bálint, B. L., Póliska, S., Rühl, R., & Nagy, L. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.052 · Cited by 37
Application of principal component analysis to pharmacogenomic studies in Canada
Visscher, H., Ross, C. J., Dubé, M., Brown, A. M. K., Phillips, M. S., Carleton, B., & Hayden, M. R. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.36 · Cited by 26
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationBurridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Self-citationRegulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Self-citationLyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citationCardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment
Lenneman, C. G., & Sawyer, D. B. (2016) · Circulation Research · doi:10.1161/circresaha.115.303633 · Cited by 469
Metadata
- Authors
- Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Amstutz, U., Rieder, M. J., Bernstein, D., Carleton, B. C., Hayden, M. R., Ross, C. J. D., The Canadian Pharmacogenomics Network for Drug Safety Consortium, Hayden, M. R., Carleton, B. C., Ross, C. J. D., MacLeod, S., Smith, A., Hildebrand, C., Ghannadan, R., Rassekh, S. R., Visscher, H., Aminkeng, F., Miao, F., Higginson, M., Massah, N., Borrie, A., Amstutz, U., Hughes, S., Shaw, K., Dhoot, S., Bhavsar, A. P., Li, Y., Lee, J. W., Kowalec, K., Stortz, J., Bendyshe-Walton, T., Waltrip, D., Bader, R., Nijssen-Jordan, C., Johnson, D., Verbeek, L., Kaczowka, R., Stevenson, P., Zhuwaki, C., Grundy, P., Stobart, K., Wilson, B., Desai, S., Spavor, M., Churcher, L., Chow, T., Hall, K., Honcharik, N., Israels, S., Chan, S., Garnham, B., Staub, M., 't Jong, G., Rieder, M. J., Malkin, B., Portwine, C., Cranston, A., Koren, G., Ito, S., Nathan, P., Greenberg, M., Bournissen, F. G., Inoue, M., Sakaguchi, S., Tanaka, T., Fujii, H., Ogawa, M., Ingram, R., Kamiya, T., Karande, S., Ghayoori, S., Silva, M., Willing, S., Vaillancourt, R., Johnston, D., Mankoo, H., Wong, E., Wilson, B., O'Connor, L., Hui, C., Yuen, C., Bussières, J.-F., Lebel, D., Barret, P., Clauson, A., Courbon, E., Cerruti, L., Jabado, N., Santo, A. E., Nagy, M., Murray, M., Boliver, D., Tiller, M., Osborne, C.-A., Goodyear, L., Bowes, L., Kean, N., & Hand, J.
- Venue
- Nature Genetics
- Published
- 2015-08-03
- Volume
- 47
- Issue
- 9
- Pages
- 1079-1084
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2227148039
- Cited by
- 278
- References
- 49
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.